Skip to main content
Erschienen in: Virchows Archiv 5/2013

01.05.2013 | Original Article

Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus

verfasst von: Johannes L. Blaauwgeers, Ingrid Kappers, Houke M. Klomp, José S. Belderbos, Lea M. Dijksman, Egbert F. Smit, Pieter E. Postmus, Marinus A. Paul, Jan W. Oosterhuis, Koen J. Hartemink, Cornelis G. Vos, Jacobus A. Burgers, Max Dahele, Erik C. Phernambucq, Birgit I. Witte, Erik Thunnissen

Erschienen in: Virchows Archiv | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The objective was to define the relationship between histopathological changes after pre-operative chemo-radiotherapy (CRT) and clinical outcome following tri-modality therapy in patients with superior sulcus tumours. A retrospective analysis of tumour material was performed in a series of 46 patients who received tri-modality therapy between 1997 and 2007. Median follow-up was 34 months (5–154). Pathological complete response (pCR) was present in 20/46 tumours (43 %). The most common RECIST score after CRT in patients with pCR was a partial response (PR; 10/17, three unknown), whereas in patients without a pCR, stable disease was the most common (22/26) (p = 0.002). In 26 specimens with residual tumour, this was mainly located in the periphery of the lesion rather than the centre (Spearman’s correlation = 0.67, p < 0.001). Prognosis was significantly better after a pCR compared to residual tumour (70 % 5-year overall survival vs. 20 %; p = 0.001) and in patients with fewer than 10 % vital tumour cells as compared to those with >10 % (65 % 5-year overall survival vs. 18 %; p < 0.001). A low mitotic count was associated with a longer disease-free survival (p = 0.02). Complete pathological response and the presence of fewer than 10 % vital tumour cells after pre-operative CRT are both associated with a more favourable prognosis. A modification of the pathological staging system after radiotherapy, incorporating the percentage of vital tumour cells, is proposed.
Literatur
1.
Zurück zum Zitat Chansky K, Sculier J-P, Crowley JJ, Giroux D, van Meerbeeck J, Goldstraw P (2009) The International Association for the Study of Lung Cancer staging project. Prognostic factors and pathologic TNM stage in surgically managed non small cell lung cancer. J Thor Oncol 4:729–801CrossRef Chansky K, Sculier J-P, Crowley JJ, Giroux D, van Meerbeeck J, Goldstraw P (2009) The International Association for the Study of Lung Cancer staging project. Prognostic factors and pathologic TNM stage in surgically managed non small cell lung cancer. J Thor Oncol 4:729–801CrossRef
2.
Zurück zum Zitat Takeda S, Maeda H, Okada T, Yamaguchi T, Nakagawa M, Yokota S, Sawabata N, Ohta M (2006) Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA–IIIB) lung cancer. Eur J Cardiothorac Surg 30:184–189PubMedCrossRef Takeda S, Maeda H, Okada T, Yamaguchi T, Nakagawa M, Yokota S, Sawabata N, Ohta M (2006) Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA–IIIB) lung cancer. Eur J Cardiothorac Surg 30:184–189PubMedCrossRef
3.
Zurück zum Zitat Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM (2009) Outcomes of patients with stage III non small cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115:4156–4166PubMedCrossRef Caglar HB, Baldini EH, Othus M, Rabin MS, Bueno R, Sugarbaker DJ, Mentzer SJ, Jänne PA, Johnson BE, Allen AM (2009) Outcomes of patients with stage III non small cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115:4156–4166PubMedCrossRef
4.
Zurück zum Zitat Kappers I, van Sandick JW, Burgers JA, Belderbos JS, Wouters MW, van Zandwijk N, Klomp HM (2009) Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg 36:741–746PubMedCrossRef Kappers I, van Sandick JW, Burgers JA, Belderbos JS, Wouters MW, van Zandwijk N, Klomp HM (2009) Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur J Cardiothorac Surg 36:741–746PubMedCrossRef
5.
Zurück zum Zitat Peedell C, Dunning J, Bapusamy A (2010) Is there a standard of care for the radical management of non-small cell lung cancer involving the apical chest wall (Pancoast tumours)? Clin Oncol 22:334–346CrossRef Peedell C, Dunning J, Bapusamy A (2010) Is there a standard of care for the radical management of non-small cell lung cancer involving the apical chest wall (Pancoast tumours)? Clin Oncol 22:334–346CrossRef
6.
Zurück zum Zitat Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F (2008) Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg 33:829–836PubMedCrossRef Pourel N, Santelmo N, Naafa N, Serre A, Hilgers W, Mineur L, Molinari N, Reboul F (2008) Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg 33:829–836PubMedCrossRef
7.
Zurück zum Zitat Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D (2007) Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25:313–318PubMedCrossRef Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D (2007) Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25:313–318PubMedCrossRef
8.
Zurück zum Zitat Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM (1997) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123:469–477PubMedCrossRef Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Müller KM (1997) Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123:469–477PubMedCrossRef
9.
Zurück zum Zitat Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC (2003) Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 16:1102–1108PubMedCrossRef Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC (2003) Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 16:1102–1108PubMedCrossRef
10.
Zurück zum Zitat Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H, Ochiai A (2010) A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy. The prognostic importance of the area of residual tumor. J Thor Oncol 5:49–55CrossRef Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H, Ochiai A (2010) A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy. The prognostic importance of the area of residual tumor. J Thor Oncol 5:49–55CrossRef
11.
Zurück zum Zitat Detterbeck FC (2003) Changes in the treatment of Pancoast tumors. Ann Thorac Surg 75:1990–1997PubMedCrossRef Detterbeck FC (2003) Changes in the treatment of Pancoast tumors. Ann Thorac Surg 75:1990–1997PubMedCrossRef
12.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
13.
Zurück zum Zitat Curtin F, Schulz P (1998) Multiple correlations and Bonferroni’s correction. Biol Psychiatry 44:775–777PubMedCrossRef Curtin F, Schulz P (1998) Multiple correlations and Bonferroni’s correction. Biol Psychiatry 44:775–777PubMedCrossRef
14.
Zurück zum Zitat Thunnissen FB, Schuurbiers OC, den Bakker MA (2006) A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology 48(7):779–786PubMedCrossRef Thunnissen FB, Schuurbiers OC, den Bakker MA (2006) A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology 48(7):779–786PubMedCrossRef
15.
Zurück zum Zitat Fischer S, Darling G, Pierre AF, Sun A, Leighl N, Waddell TK, Keshavjee S, de Perrot M (2008) Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. Eur J Cardiothorac Surg 33:1129–1134PubMedCrossRef Fischer S, Darling G, Pierre AF, Sun A, Leighl N, Waddell TK, Keshavjee S, de Perrot M (2008) Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. Eur J Cardiothorac Surg 33:1129–1134PubMedCrossRef
16.
Zurück zum Zitat Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRef Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRef
17.
Zurück zum Zitat Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher AH (2009) Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 20:231–238PubMedCrossRef Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher AH (2009) Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 20:231–238PubMedCrossRef
18.
Zurück zum Zitat Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40PubMedCrossRef Harrison L, Blackwell K (2004) Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 9(Suppl 5):31–40PubMedCrossRef
19.
Zurück zum Zitat Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1:453–458PubMed Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1:453–458PubMed
20.
Zurück zum Zitat Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068PubMedCrossRef Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068PubMedCrossRef
21.
Zurück zum Zitat Rami-Porta R, Crowley JJ, Goldstraw P (2009) The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15:4–9PubMed Rami-Porta R, Crowley JJ, Goldstraw P (2009) The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15:4–9PubMed
22.
Zurück zum Zitat Goldstraw P (2009) The IASLC staging manual in thoracic oncology. Editorial Rx, Orange Park, pp 37–38 Goldstraw P (2009) The IASLC staging manual in thoracic oncology. Editorial Rx, Orange Park, pp 37–38
23.
Zurück zum Zitat Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530PubMedCrossRef Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530PubMedCrossRef
Metadaten
Titel
Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus
verfasst von
Johannes L. Blaauwgeers
Ingrid Kappers
Houke M. Klomp
José S. Belderbos
Lea M. Dijksman
Egbert F. Smit
Pieter E. Postmus
Marinus A. Paul
Jan W. Oosterhuis
Koen J. Hartemink
Cornelis G. Vos
Jacobus A. Burgers
Max Dahele
Erik C. Phernambucq
Birgit I. Witte
Erik Thunnissen
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 5/2013
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1404-6

Weitere Artikel der Ausgabe 5/2013

Virchows Archiv 5/2013 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …